NEW RAY MEDIC(06108.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
NEW RAY MEDIC
06108.HK
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin a1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B, and chronic hepatitis C; and cefamandole nafate, ceftizoxime sodium, and isepamicin sulfate injection for the treatment of respiratory tract infections, genitourinary system infections, urinary tract infections, intra-abdominal infections, bone, joint infections, and septicemia. It also provides alanyl glutamine for injection that is indicated for catabolism and hypermetabolism; cefixime dispersible tablets to treat infections caused by streptococcus and pneumococcus, chronic bronchitis, acute bronchitis with bacterial infection, pneumonia, pyelonephritis, cystitis, gonococcal urethritis, and acute bacterial infection of the biliary tract system; and clostridium butyricum capsule for diarrhea and digestive system relevant illness. Further, the company offers marketing and promotion services.
181.48 B
06108.HKMarket value -Rank by Market Cap -/-

Financial Score

21/01/2026 Update
C
Health Care DistributorsIndustry
Industry Ranking16/21
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-7.70%D
    • Profit Margin-28.20%E
    • Gross Margin8.13%E
  • Growth ScoreB
    • Revenue YoY240.05%A
    • Net Profit YoY-166.48%E
    • Total Assets YoY-9.68%E
    • Net Assets YoY-9.45%D
  • Cash ScoreC
    • Cash Flow Margin-354.66%D
    • OCF YoY240.05%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreA
    • Gearing Ratio5.12%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Movement Update: Anteris Tech surges 41.74%, Corvus Pharma drops 10.09% attracting attention

    In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology stocks and the biopharmaceutical sector performing particularly well. The strong rise of Anteris Tech Global has attracted a significant inflow of funds, while Corvus Pharma has faced notable selling pressure, indicating a polarization of market sentiment. Short-term enthusiasm has increased among small-cap stocks, especially with active performances from individual stocks like Moolec Science and Senmiao Tech, driving fluctuations in related sectors. Overall, the market pace is relatively fast, with funds frequently switching between different themes, leading to increased volatility. The stock with the largest movement in the past hour, Anteris Tech Global, surged by 41.74%, becoming the market's focal point. The stock quickly rose after the opening, attracting a large amount of short-term funds, with sentiment high, seemingly indicating an optimistic outlook for its future prospects. Strong stocks include: 1. Moolec Science SA: up 9.11%, driven by recent market expectations for its new products, with active short-term funds. 2. Senmiao Tech: up 7.75%, performing well against the backdrop of an overall recovery in technology stocks, attracting considerable investor attention. 3. Rezolve AI: up 7.61%, with the company's recent technological advancements igniting market enthusiasm and noticeable fund inflows

    Tracking Unusual Activity·
    Tracking Unusual Activity·

    In the Hong Kong stock market, the Hang Seng Index fell 39 points in the first half of the day, Anta dropped over 5%, and SMIC HUA HONG SEMI rose

    The Hong Kong stock market opened softly, with the Hang Seng Index down 39 points at 26,447 points. The National Index fell 24 points, while the Hang Seng Tech Index rose 8 points. The total turnover was HKD 127.653 billion. Anta dropped over 5%, while SMIC rose 4.7%. Baidu's stock price increased by 3.3% due to a target price adjustment. Technology stocks showed mixed performance, with Tencent slightly down 0.2% and Alibaba up 1.1%. In the automotive sector, BYD rose 1.1%

    AASTOCKS·
    HK
    01347
    +4.97%
    HK
    00HSI
    +0.03%
    HK
    09888
    +3.23%
    AASTOCKS·
    HK
    01347
    +4.97%
    HK
    00HSI
    +0.03%
    HK
    09888
    +3.23%

    In the Hong Kong stock market, the Hang Seng Index fell 11 points in the first half of the day, while POP MART rose over 8%, with consumer stocks showing an upward trend

    The Hong Kong stock market fluctuated in the early session, with the Hang Seng Index opening down 19 points, rising a maximum of 74 points before retreating, ultimately closing down 11 points at 26,552 points. The National Index and the Hang Seng Tech Index fell by 11 points and 38 points, respectively. The total turnover was HKD 129.845 billion. Technology stocks generally declined, with Tencent, Baidu, Alibaba, and others all experiencing drops, while only JD.com and Bilibili saw slight increases. Consumer stocks performed relatively strongly, with POP MART rising over 8%

    AASTOCKS·
    HK
    09992
    -2.54%
    AASTOCKS·
    HK
    09992
    -2.54%

    Grand Pharmaceutical Says Imaging Agent Accepted For Chinese Regulatory Review

    Grand Pharmaceutical Says Imaging Agent Accepted For Chinese Regulatory Review

    marketscreener·
    SZ
    000626
    +0.51%
    SZ
    000963
    -1.06%
    marketscreener·
    SZ
    000626
    +0.51%
    SZ
    000963
    -1.06%

    Hong Kong stocks fell 281 points, Alibaba dropped 4%, biotech stocks were sold off, and Li Ning rose 3% against the trend. Experts: The upward wave at the beginning of the year has ended | Hong Kong stock market closing

    The Hong Kong stock market closed down 281 points today, reporting at 26,563 points, marking a three-day decline, with a turnover of HKD 225.6 billion. Alibaba fell by 4%, and biotechnology stocks performed poorly, with both the Hang Seng Index and the Tech Index also declining. Despite the A-shares stabilizing after the release of mainland economic data, the Hong Kong stock market remains in an adjustment phase, with a short-term support level expected at 26,000 points. LI NING rose by 3% against the trend

    Stheadline·
    US
    BABA
    -1.82%
    HK
    09988
    +1.13%
    HK
    02331
    -3.45%
    Stheadline·
    US
    BABA
    -1.82%
    HK
    09988
    +1.13%
    HK
    02331
    -3.45%
    © 2026 Longbridge｜Disclaimer